Want to see BTTC full AI Analyst Report?
BTTC Stock Chart & Stats
$0.89
$0.06(6.35%)
At close: 4:00 PM EDT
$0.89
$0.06(6.35%)
Day’s Range― - ―
52-Week Range$0.64 - $39.00
Previous CloseN/A
Volume787.00
Average Volume (3M)508.16K
Market Cap
$7.40M
Enterprise Value-$66.93M
Total Cash (Recent Filing)$74.09M
Total Debt (Recent Filing)$825.70K
Price to Earnings (P/E)12375891776014100.0
Beta0.67
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding10,774,621
10 Day Avg. Volume493,518
30 Day Avg. Volume508,156
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00140
P/FCF Ratio0.01
Enterprise Value/Market Cap-9.04
Enterprise Value/Revenue-18.99
Enterprise Value/Gross Profit-55.99
Enterprise Value/Ebitda132.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)17.4
Revenue Forecast (FY)$35.35M
Bulls Say, Bears Say
Bulls Say
Cash Flow ImprovementImprovement in free cash flow, although slight, indicates progress towards better cash management, which is crucial for sustaining operations and reducing reliance on external financing.
Strategic PartnershipsStrategic partnerships can provide Titan with additional revenue streams and access to new markets, enhancing its competitive position and supporting long-term growth prospects.
No DebtHaving no debt provides Titan Pharmaceuticals with greater financial flexibility and reduces the risk of financial distress, allowing it to focus resources on operational improvements and strategic initiatives.
Bears Say
Operational InefficienciesOperational inefficiencies leading to net losses reflect high expenses relative to revenue, posing a significant barrier to achieving sustainable profitability and growth.
Negative Cash FlowsNegative cash flows highlight difficulties in generating sufficient cash from operations, which may necessitate further external financing and impact financial stability.
Declining RevenuesThe persistent decline in revenues suggests challenges in market demand or competitive positioning, which can undermine long-term business viability and investor confidence.
Black Titan News
BTTC FAQ
What was Black Titan’s price range in the past 12 months?
Black Titan lowest stock price was $0.64 and its highest was $39.00 in the past 12 months.
What is Black Titan’s market cap?
Black Titan’s market cap is $7.40M.
When is Black Titan’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Black Titan’s earnings last quarter?
Black Titan released its earnings results on Nov 13, 2023. The company reported -$0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.022.
Is Black Titan overvalued?
According to Wall Street analysts Black Titan’s price is currently Overvalued.
Does Black Titan pay dividends?
Black Titan does not currently pay dividends.
What is Black Titan’s EPS estimate?
Black Titan’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Black Titan have?
Black Titan has 10,774,621 shares outstanding.
What happened to Black Titan’s price movement after its last earnings report?
Black Titan reported an EPS of -$0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.556%.
Which hedge fund is a major shareholder of Black Titan?
Currently, no hedge funds are holding shares in BTTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Black Titan
Titan Pharmaceuticals, Inc. (TTNP) is a biopharmaceutical company focused on developing and commercializing innovative treatments for serious medical conditions. With a strong emphasis on the central nervous system and opioid addiction treatment markets, Titan's core product is Probuphine, a unique subdermal implant designed to deliver a continuous and controlled dose of buprenorphine for opioid dependence management.
Technical Analysis
―
Binah Capital Group
―
Beneficient
―
CaliberCos, Inc. Class A
―
Mount Logan Capital Inc
―
Ownership Overview
― Insiders
0.01% Mutual Funds
0.51% Other Institutional Investors
99.48% Public Companies and
Individual Investors